Group 1 - Guizhou Moutai elected Chen Hua as the chairman of the fourth board of directors [4] - Tianfeng Securities is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure and illegal financing [4] - Yongtai Energy's actual controller Wang Guangxi received a notice of investigation from the China Securities Regulatory Commission for matters unrelated to the company [4] Group 2 - Shenzhou Pharmaceutical's controlling shareholder plans to reduce its stake by no more than 3% [4] - Zhenhua Group intends to increase its stake in China Jushi by 550 million to 1.1 billion yuan [4] - Jihong Co., Ltd. and its concerted parties plan to reduce their stake by no more than 2.93% [4] Group 3 - XJ Electric won a 1.518 billion yuan procurement project from the State Grid [4] - China XD Electric's subsidiaries collectively won procurement projects from the State Grid worth approximately 2.98 billion yuan [4] - Chaozhuo Aerospace's actual controller will change to the Hubei Provincial State-owned Assets Supervision and Administration Commission, with stock resuming trading on December 1 [4] Group 4 - Huakong Saige terminated its specific object stock issuance [5] - Shenzhen Energy plans to apply for a public bond issuance with a total scale not exceeding 20 billion yuan [5] Group 5 - Blue Sail Medical's board proposed to lower the conversion price of "Blue Sail Convertible Bonds" [6] - ST Lifang's stock will be subject to delisting risk warning and will be suspended from trading on December 1 [7] - Cambrian elected Chen Tianshi as chairman [8]

证券日报网讯 11月28日晚间，神奇制药发布公告称，截至本公告披露日，上海神奇制药投资管理股份 有限公司（以下简称"公司"）股东张之君先生持有公司股份26，703，050股，占公司总股本的 4.9999%。上述股份来源于2018年12月通过协议转让取得。张之君先生系公司控股股东贵州神奇控股 （集团）公司的一致行动人。本次减持计划自本公告披露之日起15个交易日后的3个月内实施，且在任 意连续90日内，通过上海证券交易所集中竞价交易减持股份的总数不超过公司股份总数的1%、通过上 海证券交易所大宗交易减持股份的总数不超过公司股份总数的2%。 （文章来源：证券日报） ...

Key Points - Guizhou Moutai elected Chen Hua as the chairman of the fourth board of directors and plans to repurchase shares between RMB 1.5 billion and RMB 3 billion [1] - Tianfeng Securities is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure and illegal financing [1] Share Buybacks - Demai Technology raised the upper limit for share repurchase to RMB 45 per share [5] - Jianbang Technology plans to repurchase shares worth between RMB 15 million and RMB 30 million [5] - Huayuan Holdings intends to repurchase shares worth between RMB 30 million and RMB 60 million [5] Major Investments - Jinling Pharmaceutical plans to invest RMB 893 million in hospital expansion projects [7] - Dongfang Mingzhu intends to invest approximately RMB 500 million to establish a partnership and acquire part of the equity of New H3C [7] - Chang'an Automobile aims to establish a robotics company to develop innovative products and solutions [7] Mergers and Acquisitions - Kaizhong Co. plans to acquire 60% of Anhui Tuosheng's equity, with stock resuming trading on December 1 [7] - Youa Co. has resumed the review process for issuing shares and cash to purchase assets [7] - Jiasheng Technology intends to acquire controlling interest in Shudun Information Technology Co., with stock continuing to be suspended [7] Financing Activities - Shenzhen Energy plans to apply for a public bond issuance with a total scale not exceeding RMB 20 billion [7] - Huakong Saige has terminated its specific object stock issuance [7]

900904 神奇 B 股 证券代码：600613 证券简称：神奇制药 公告编号：2025-040 上海神奇制药投资管理股份有限公司 关于控股股东的一致行动人减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，上海神奇制药投资管理股份有限公司（以下简称"公 司"）股东张之君先生持有公司股份 26,703,050 股，占公司总股本的 4.9999%。 上述股份来源于 2018 年 12 月通过协议转让取得。张之君先生系公司控股股东贵 州神奇控股（集团）公司的一致行动人。 减持计划的主要内容 张之君先生因个人资金需要，计划通过集中竞价交易和大宗交易方式减持其 持有的公司股份不超过 16,022,148 股。 本次减持计划自本公告披露之日起 15 个交易日后的 3 个月内实施，且 在任意连续 90 日内，通过上海证券交易所集中竞价交易减持股份的总数不超过 公司股份总数的 1%、通过上海证券交易所大宗交易减持股份的总数不超过公司 股份总数的 2%。 上述期 ...

人民财讯11月28日电，神奇制药（维权）(600613)11月28日公告，控股股东之一致行动人张之君因个人 资金需要计划通过集中竞价交易和大宗交易方式减持其持有的公司股份不超过1602.21万股，即不超过 公司总股本的3%。 转自：证券时报 ...

格隆汇11月28日丨神奇制药（维权）(600613.SH)公布,张之君先生因个人资金需要，计划通过集中竞价 交易和大宗交易方式减持其持有的公司股份不超过1602.21万股。本次减持计划自本公告披露之日起15 个交易日后的3个月内实施，且在任意连续90日内，通过上海证券交易所集中竞价交易减持股份的总数 不超过公司股份总数的1%、通过上海证券交易所大宗交易减持股份的总数不超过公司股份总数的2%。 ...

神奇制药（600613）(600613.SH)发布公告，公司控股股东的一致行动人张之君因个人资金需要，计划 通过集中竞价交易和大宗交易方式减持其持有的公司股份不超过1602.21万股，减持比例不超过3%。 ...

据神奇制药公告，股东张之君因个人资金需要，计划通过集中竞价交易和大宗交易方式减持其持有的公 司股份不超过1,602.21万股，占公司总股本的3%。其中，集中竞价减持不超过534.07万股，大宗交易减 持不超过1,068.14万股。减持期间为2025年12月22日至2026年3月20日。 ...

Core Viewpoint - The unexpected tax payment of approximately 16.67 million yuan by Guizhou Baiqiang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shenqi Pharmaceutical, adds pressure to the company's growth and will directly impact its 2025 performance [2][5][11]. Financial Impact - The tax payment and late fees amount to 16.67 million yuan, which represents 33.12% of Shenqi Pharmaceutical's net profit of 50.3 million yuan for the first three quarters of 2025 [5][10]. - The company's revenue for the same period was 1.398 billion yuan, indicating that the tax payment significantly affects profitability [5]. Market Reaction - Despite the negative news, the market reacted relatively calmly, with Shenqi Pharmaceutical's stock price closing at 6.48 yuan, a slight increase of 1.25%, and a market capitalization of 3.46 billion yuan [4]. - On November 25, the stock price rose over 4%, influenced by movements in the flu sector [4]. Internal Control Issues - This incident is not the first time Shenqi Pharmaceutical has faced scrutiny over financial compliance, as it previously received regulatory warnings for fabricating consulting fees to misappropriate funds [6][7]. - The tax payment issue highlights potential weaknesses in the company's internal controls and financial oversight of its subsidiaries [11]. Industry Context - Shenqi Pharmaceutical operates in a challenging environment characterized by policy pressures such as volume-based procurement and medical insurance cost control, which affect the pharmaceutical industry as a whole [9]. - The company's high price-to-earnings ratio of 51.6 suggests that its stock price may have already priced in future growth expectations [8].

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]